Mulvey MR, et al. - This systematic review aimed to assess the methodological quality of rigorous neuropathic pain assessment tools in applicable clinical studies and to determine the performance of screening tools for identifying neuropathic pain in patients with cancer. In patients with cancer pain, the authors identified concordance between the clinician diagnosis and screening tool outcomes for Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), Douleur Neuropathique en 4 (DN4) or painDETECT (PDQ). In screening tool sensitivity, shortcomings in relation to standardized clinician assessment probably accounted for variation, which had to include the use of the neuropathic pain grading system. To standardize and improve clinical assessment in patients with cancer pain, further research was required. Screening tools offered a practical approach to identify potential cases of neuropathic cancer pain until the standardization of clinical diagnosis for neuropathic cancer pain had been validated.